All In Biotech

Free tool

FAERS Monitor: Brytly

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 220341 or its brand name (Brytly, Apraclonidine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

20

Serious

12

60% of reports

Hospitalization

2

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • adrenal insufficiency3
  • drug intolerance3
  • injection site reaction3
  • vaginal infection3
  • drug ineffective2
  • heart rate increased2
  • vision blurred2
  • visual impairment2
  • abdominal distension1
  • abdominal pain upper1
  • activities of daily living impaired1
  • affective disorder1
  • blood pressure increased1
  • bone pain1
  • cardiac disorder1

Reports by year received

View as table
YearReports
20051
20081
20091
20112
20121
20162
20203
20212
20223
20231
20242
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,139 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vaginal infectionSignal3670.8236.21,392
adrenal insufficiencySignal3260.191.6537
affective disorder1133.819.832
activities of daily living impaired153.17.912
injection site reactionSignal345.916.291
drug intoleranceSignal332.711.563
heart rate increased221.25.721
bone pain118.02.74
visual impairment217.04.616
vision blurred215.34.114
cardiac disorder111.21.72
abdominal distension110.11.52
blood pressure increased16.91.01
abdominal pain upper15.10.80
drug ineffective21.60.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.